21 CFR Part 56 Flashcards

1
Q

what does 21 CFR Part 56 cover?

A

general standards for the composition, operation, and responsibility of an Institutional Review Board (IRB)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

emergency use

A

use of a test article on a human subject in a life-threatening situation in which no standard acceptable treatment is available, and there is not sufficient time to obtain IRB approval.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

IRB approval

A

the determination of the IRB that the clinical investigation has been reviewed and may be conducted at an institution within the constraints set forth by the IRB

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

When is IRB review required?

A

any clinical investigation which must meet the requirements for prior submission to the FDA shall not be initiated unless that investigation has been reviewed and approved by, and remains subject to continuing review by, an IRB.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Exemption from IRB requirement

(4 conditions)

A
  1. Any investigation which started before July 27, 1981 and was subject to IRB review
  2. Any investigation commenced before July 27, 1981 and was not otherwise subject to requirements for IRB review
  3. Emergency use of a test article, provided that such emergency use is reported to the IRB within 5 working days.
  4. Taste and food quality evaluations and consumer acceptance studies, if wholesome foods without additives are consumed or if a food is consumed that contains a food ingredient at or below the level and for a use found to be safe,
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Waiver of IRB requirement

A

On the application of a sponsor or sponsor-investigator, the FDA may waive any of the requirements contained in these regulations, including the requirements for IRB review, for specific activities

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

IRB registration- who must register?

A

Each IRB in the US that reviews clinical investigations regulated by FDA and each IRB in the US that reviews clinical investigations that are intended to support applications for research or marketing permits for FDA-regulated products must register at a site maintained by the DHHS.
*An individual authorized to act on the IRB’s behalf must submit the registration information.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

What information must an IRB register?

A
  1. Name, mailing address, street address of the institution operating the IRB & the name, mailing address, phone #, fax #, and email the senior officer of that institution who is responsible for overseeing activities performed by the IRB;
  2. The IRB’s name, mailing address, street address, phone #, fax #, and email address; each IRB chairperson’s name, phone #, and email address; and the name, mailing address, phone #, fax #, and email of the contact person providing the registration information.
  3. The approximate #of active protocols involving FDA-regulated products reviewed.
  4. A description of the types of FDA-regulated products (such as biological products, color additives, food additives, human drugs, or medical devices) involved in the protocols that the IRB reviews.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

When must an IRB register?

A

Each IRB must renew its registration every 3 years

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Where can an IRB register?

A

online at OHRP

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

How does an IRB revise its registration information?

A

If an IRB’s contact or chair person information changes, the IRB must revise its registration information by submitting any changes in that information within 90 days of the change.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

IRB membership

(6 conditions)

A
  1. IRB shall have at least 5 members, with varying backgrounds to promote complete and adequate review of research activities commonly conducted by the institution.
  2. Every nondiscriminatory effort will be made to ensure that no IRB consists entirely of 1 sex or race or profession.
  3. Each IRB shall include at least 1member whose primary concerns are in the scientific area and at least 1 member whose primary concerns are in nonscientific areas.
  4. Each IRB shall include at least one member who is not affiliated with the institution and who is not part of the immediate family of a person who is affiliated with the institution.
  5. No IRB may have a member participate in the IRB’s initial or continuing review of any project in which the member has a conflicting interest.
  6. IRB may invite individuals with competence in special areas to assist in the review of complex issues These individuals may not vote with the IRB.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

IRB functions and operations

A
  1. Follow written procedures:
    • For conducting its initial and continuing review of research and reporting its findings and actions to the investigator and institution;
    • determining which projects require review more often than annually and which projects
    • ensuring prompt reporting to the IRB of changes in research activity;
    • ensuring that changes in approved research, during the period for which IRB approval has already been given, may not be initiated without IRB review
  2. Follow written procedures for ensuring prompt reporting to the IRB, officials, and the FDA of:
    • unanticipated problems involving risks to human subjects or others;
    • any instance of serious or continuing noncompliance with these regulations
    • any suspension or termination of IRB approval.
  3. review proposed research at convened meetings at which a majority of the members of the IRB are present,
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

IRB review of research

(8)

A
  1. An IRB shall review and have authority to approve, require modifications or disapprove all research activities covered by these regulations.
  2. An IRB shall require that information given to subjects as part of informed consent is in accordance with
  3. An IRB shall require documentation of informed consent
  4. In cases where the documentation requirement is waived the IRB may require the investigator to provide subjects with a written statement regarding the research.
  5. An IRB shall notify investigators and the institution in writing of its decision to approve or disapprove the proposed research activity, or of modifications required to secure IRB approval of the research activity. If the IRB decides to disapprove a research activity, it shall include in its written notification a statement of the reasons for its decision and give the investigator an opportunity to respond in person or in writing.
  6. An IRB shall conduct continuing review of research covered by these regulations at intervals appropriate to the degree of risk, but not less than once per year,
  7. An IRB shall provide in writing to the sponsor of research involving an exception to informed consent
  8. When some or all of the subjects in a study are children, an IRB must determine that the research study is in compliance
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Expedited review procedures

A

The FDA has established, and published in the Federal Register, a list of categories of research that may be reviewed by the IRB through an expedited review procedure.

-An IRB may use the expedited review procedure to review either or both of the following:

  1. Some or all of the research appearing on the list and found by the reviewer(s) to involve no more than minimal risk,
  2. minor changes in previously approved research during the period (of 1 year or less) for which approval is authorized.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Criteria for IRB approval of research

(7 requirements)

A

In order to approve research the IRB shall determine that all of the following requirements are satisfied:

(1) Risks to subjects are minimized:
(2) Risks to subjects are reasonable in relation to anticipated benefits
(3) Selection of subjects is equitable.
(4) Informed consent will be sought from each prospective subject or the subject’s legally authorized representative.
(5) Informed consent will be appropriately documented,
(6) The research plan makes adequate provision for monitoring the data collected to ensure the safety of subjects.
(7) There are adequate provisions to protect the privacy of subjects and to maintain the confidentiality of data.

17
Q

Review by institution

A

Research covered by these regulations that has been approved by an IRB may be subject to further appropriate review and approval or disapproval by officials of the institution.

18
Q

Suspension or termination of IRB approval of research

A

An IRB shall have authority to suspend or terminate approval of research that is not being conducted in accordance with the IRB’s requirements or that has been associated with unexpected serious harm to subjects.

19
Q

Cooperative research

A

Institutions involved in multi-institutional studies may use joint review, reliance upon the review of another qualified IRB, or similar arrangements aimed at avoidance of duplication of effort.

20
Q

IRB Records

A

An institution, or an IRB, shall prepare and maintain adequate documentation of IRB activities, including the following:

(1) Copies of all research proposals reviewed, sample consent documents, progress reports submitted by investigators, and reports of injuries to subjects.
(2) Minutes of IRB meetings which shall be in sufficient detail
(3) Records of continuing review activities.
(4) Copies of all correspondence between the IRB and the investigators.
(5) A list of IRB members identified by name; earned degrees etc.
(6) Written procedures for the IRB
(7) Statements of significant new findings provided to subjects

* The records required by this regulation shall be retained for at least 3 years after completion of the research
* The FDA may refuse to consider a clinical investigation if the institution or the IRB that reviewed the investigation refuses to allow an inspection under this section.

21
Q

Lesser administrative actions

A

-If apparent noncompliance with these regulations in the operation of an IRB is observed by an FDA investigator during an inspection, the inspector will present an oral or written summary of observations to an appropriate representative of the IRB. The Food and Drug Administration may subsequently send a letter describing the noncompliance to the IRB and to the parent institution. The agency will require that the IRB or the parent institution respond to this letter within a time period specified by FDA and describe the corrective actions that will be taken by the IRB, the institution, or both to achieve compliance with these regulations.

  • On the basis of the IRB’s or the institution’s response, FDA may schedule a reinspection to confirm the adequacy of corrective actions. In addition, until the IRB or the parent institution takes appropriate corrective action, the Agency may require the IRB to:
    (1) Withhold approval of new studies
    (2) Direct that no new subjects be added to ongoing studies subject to this part; or
    (3) Terminate ongoing studies subject to this part when doing so would not endanger the subjects.
  • When the noncompliance creates a significant threat to the rights and welfare of human subjects, FDA may notify relevant State and Federal regulatory agencies
  • The parent institution is presumed to be responsible for the operation of an IRB, and the Food and Drug Administration will ordinarily direct any administrative action under this subpart against the institution.
22
Q

Disqualification of an IRB or an institution.

A
  • Whenever the IRB or the institution has failed to take adequate steps to correct the noncompliance stated in the letter sent by the agency and the Commissioner of Food and Drugs determines that this noncompliance may justify the disqualification of the IRB or of the parent institution, the Commissioner will institute proceedings in accordance with the requirements for a regulatory hearing set forth in part 16.
  • The Commissioner may disqualify an IRB or the parent institution if the Commissioner determines that:
    (1) The IRB has refused or repeatedly failed to comply with any of the regulations set forth in this part, and
    (2) The noncompliance adversely affects the rights or welfare of the human subjects in a clinical investigation.
  • If the Commissioner determines that disqualification is appropriate, the Commissioner will issue an order that explains the basis for the determination and that prescribes any actions to be taken with regard to ongoing clinical research conducted under the review of the IRB.
  • The FDA will not approve an application for a research permit for a clinical investigation that is to be under the review of a disqualified IRB
23
Q

Public disclosure of information regarding revocation.

A

A determination that the FDA has disqualified an institution and the administrative record regarding that determination are disclosable to the public under part

24
Q

Reinstatement of an IRB or an institution.

A

An IRB or an institution may be reinstated if the Commissioner determines, upon an evaluation of a written submission from the IRB or institution that explains the corrective action that the institution or IRB plans to take, that the IRB or institution has provided adequate assurance that it will operate in compliance with the standards set forth in this part.

25
Q

Actions alternative or additional to disqualification

A

Disqualification of an IRB or of an institution is independent of, and neither in lieu of nor a precondition to, other proceedings or actions authorized by the act.
-The FDA may, at any time, through the Department of Justice institute any appropriate judicial proceedings (civil or criminal) and any other appropriate regulatory action, in addition to or in lieu of, and before, at the time of, or after, disqualification.